Q4 sales fell short of expectations. Dupixent remained the key growth driver, supported by a good performance from Consumer Healthcare and somewhat offset by a weaker showing in Vaccines. Moreover, the 2023 guidance was weak. Nonetheless, given the healthy prospects of Dupixent, the strong positioning in Vaccines and the robust balance sheet, the firm has enough leeway to look for further growth opportunities. Sanofi looks attractively priced at the current levels, especially given the dissipati ....